Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

Blood

Volumn 126, Issue 6, 2015, Pages 790-797

  Patel, Keyur P ^a   Newberry, Kate J ^a   Luthra, Rajyalakshmi ^a   Jabbour, Elias ^a   Pierce, Sherry ^a   Cortes, Jorge ^a   Singh, Rajesh ^a   Mehrotra, Meenakshi ^a   Routbort, Mark J ^a   Luthra, Madan ^a   Manshouri, Taghi ^a   Santos, Fabio P ^b   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RUXOLITINIB; ANTINEOPLASTIC AGENT; ASXL1 PROTEIN, HUMAN; CALRETICULIN; DNA BINDING PROTEIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; REPRESSOR PROTEIN; TET2 PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CALR GENE; COHORT ANALYSIS; FEMALE; GATA2 GENE; GENE; GENE DELETION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAK2 GENE; KRAS GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MPL GENE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; NEXT GENERATION SEQUENCING; NRAS GENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PTPN11 GENE; RUNX1 GENE; SPLEEN SIZE; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; ODDS RATIO; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY MYELOFIBROSIS; PROGNOSIS; SPLEEN; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CALRETICULIN; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; ODDS RATIO; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; REPRESSOR PROTEINS; SPLEEN; SURVIVAL ANALYSIS;

EID: 84940099833     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-633404     Document Type: Article

References (36)

1. Guglielmelli P, Biamonte F, Rotunno G, et al COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123(14):2157-2160.
2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
3. Tenedini E, Bernardis I, Artusi V, et al; AGIMM investigators. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia. 2014;28(5):1052-1059.
4. Engle EK, Fisher DAC, Miller CA, et al. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia. 2015;29(4):869-876.
5. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714-3719.
6. Luthra R, Patel KP, Reddy NG, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99(3):465-473.
7. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645-2651.
9. Tefferi A, Barosi G, Mesa RA, et al; IWG for Myelofibrosis Research and Treatment (IWG-MRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503.
10. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202-1209.
11. Krzywinski MI, Schein JE, Birol I, et al. Circos: An information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639-1645.
12. Lee BH, Kim J-M, Jin HY, Kim G-H, Choi J-H, Yoo H-W. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J Pediatr. 2011;159(6):1029-1035.
13. Chan G, Cheung LS, Yang W, et al. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011;117(16):4253-4261.
14. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371(6494):221-226.
15. Mir MA, Kochuparambil ST, Abraham RS, et al. Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. Cancer Med. 2015;4(4):490-499.
16. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111(50):E5401-E5410.
17. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24(10):1713-1718.
18. Beer PA, Delhommeau F, LeCouédic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.
19. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.
20. Greaves WO, Verma S, Bisrat T, et al. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013;54(7):1552.
21. Raza S, Viswanatha D, Frederick L, et al. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. 2012;87(2):204-206.
22. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220-2228.
23. Milosevic JD, Puda A, Malcovati L, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012;87(11):1010-1016.
24. Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica. 2014;99(11):1697-1700.
25. Pardanani A, Abdelrahman RA, Finke C, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29(3):741-744.
26. Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25(7):1217-1219.
27. Verstovsek S, Mesa RA, Gotlib J, et al; COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479-488.
28. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457-2467.
29. Brecqueville M, Rey J, Devillier R, et al. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica. 2014;99(1):37-45.
30. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148-150.
31. Tartaglia M, Martinelli S, Iavarone I, et al. Somatic PTPN11 mutations in childhood acute myeloid leukaemia. Br J Haematol. 2005;129(3):333-339.
32. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465-468.
33. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70(6):1555-1563.
34. Zhao Q, Xie Y, Zheng Y, et al. GPS-SUMO: a tool for the prediction of sumoylation sites and SUMO-interaction motifs. Nucleic Acids Res. 2014;42 (Web Server issue W1):W325-30.
35. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905-911.
36. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601-612.